Cargando…

Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials

BACKGROUND: Blue Cone Monochromacy (BCM) is an X-linked retinopathy caused by mutations in the OPN1LW / OPN1MW gene cluster, encoding long (L)- and middle (M)-wavelength sensitive cone opsins. Recent evidence shows sufficient structural integrity of cone photoreceptors in BCM to warrant consideratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Xunda, Cideciyan, Artur V., Iannaccone, Alessandro, Roman, Alejandro J., Ditta, Lauren C., Jennings, Barbara J., Yatsenko, Svetlana A., Sheplock, Rebecca, Sumaroka, Alexander, Swider, Malgorzata, Schwartz, Sharon B., Wissinger, Bernd, Kohl, Susanne, Jacobson, Samuel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409040/
https://www.ncbi.nlm.nih.gov/pubmed/25909963
http://dx.doi.org/10.1371/journal.pone.0125700
_version_ 1782368141486063616
author Luo, Xunda
Cideciyan, Artur V.
Iannaccone, Alessandro
Roman, Alejandro J.
Ditta, Lauren C.
Jennings, Barbara J.
Yatsenko, Svetlana A.
Sheplock, Rebecca
Sumaroka, Alexander
Swider, Malgorzata
Schwartz, Sharon B.
Wissinger, Bernd
Kohl, Susanne
Jacobson, Samuel G.
author_facet Luo, Xunda
Cideciyan, Artur V.
Iannaccone, Alessandro
Roman, Alejandro J.
Ditta, Lauren C.
Jennings, Barbara J.
Yatsenko, Svetlana A.
Sheplock, Rebecca
Sumaroka, Alexander
Swider, Malgorzata
Schwartz, Sharon B.
Wissinger, Bernd
Kohl, Susanne
Jacobson, Samuel G.
author_sort Luo, Xunda
collection PubMed
description BACKGROUND: Blue Cone Monochromacy (BCM) is an X-linked retinopathy caused by mutations in the OPN1LW / OPN1MW gene cluster, encoding long (L)- and middle (M)-wavelength sensitive cone opsins. Recent evidence shows sufficient structural integrity of cone photoreceptors in BCM to warrant consideration of a gene therapy approach to the disease. In the present study, the vision in BCM is examined, specifically seeking clinically-feasible outcomes for a future clinical trial. METHODS: BCM patients (n = 25, ages 5–72) were studied with kinetic and static chromatic perimetry, full-field sensitivity testing, and eye movement recordings. Vision at the fovea and parafovea was probed with chromatic microperimetry. RESULTS: Kinetic fields with a Goldmann size V target were generally full. Short-wavelength (S-) sensitive cone function was normal or near normal in most patients. Light-adapted perimetry results on conventional background lights were abnormally reduced; 600-nm stimuli were seen by rods whereas white stimuli were seen by both rods and S-cones. Under dark-adapted conditions, 500-nm stimuli were seen by rods in both BCM and normals. Spectral sensitivity functions in the superior retina showed retained rod and S-cone functions in BCM under dark-adapted and light-adapted conditions. In the fovea, normal subjects showed L/M-cone mediation using a 650-nm stimulus under dark-adapted conditions, whereas BCM patients had reduced sensitivity driven by rod vision. Full-field red stimuli on bright blue backgrounds were seen by L/M-cones in normal subjects whereas BCM patients had abnormally reduced and rod-mediated sensitivities. Fixation location could vary from fovea to parafovea. Chromatic microperimetry demonstrated a large loss of sensitivity to red stimuli presented on a cyan adapting background at the anatomical fovea and surrounding parafovea. CONCLUSIONS: BCM rods continue to signal vision under conditions normally associated with daylight vision. Localized and retina-wide outcome measures were examined to evaluate possible improvement of L/M-cone-based vision in a clinical trial.
format Online
Article
Text
id pubmed-4409040
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44090402015-05-12 Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials Luo, Xunda Cideciyan, Artur V. Iannaccone, Alessandro Roman, Alejandro J. Ditta, Lauren C. Jennings, Barbara J. Yatsenko, Svetlana A. Sheplock, Rebecca Sumaroka, Alexander Swider, Malgorzata Schwartz, Sharon B. Wissinger, Bernd Kohl, Susanne Jacobson, Samuel G. PLoS One Research Article BACKGROUND: Blue Cone Monochromacy (BCM) is an X-linked retinopathy caused by mutations in the OPN1LW / OPN1MW gene cluster, encoding long (L)- and middle (M)-wavelength sensitive cone opsins. Recent evidence shows sufficient structural integrity of cone photoreceptors in BCM to warrant consideration of a gene therapy approach to the disease. In the present study, the vision in BCM is examined, specifically seeking clinically-feasible outcomes for a future clinical trial. METHODS: BCM patients (n = 25, ages 5–72) were studied with kinetic and static chromatic perimetry, full-field sensitivity testing, and eye movement recordings. Vision at the fovea and parafovea was probed with chromatic microperimetry. RESULTS: Kinetic fields with a Goldmann size V target were generally full. Short-wavelength (S-) sensitive cone function was normal or near normal in most patients. Light-adapted perimetry results on conventional background lights were abnormally reduced; 600-nm stimuli were seen by rods whereas white stimuli were seen by both rods and S-cones. Under dark-adapted conditions, 500-nm stimuli were seen by rods in both BCM and normals. Spectral sensitivity functions in the superior retina showed retained rod and S-cone functions in BCM under dark-adapted and light-adapted conditions. In the fovea, normal subjects showed L/M-cone mediation using a 650-nm stimulus under dark-adapted conditions, whereas BCM patients had reduced sensitivity driven by rod vision. Full-field red stimuli on bright blue backgrounds were seen by L/M-cones in normal subjects whereas BCM patients had abnormally reduced and rod-mediated sensitivities. Fixation location could vary from fovea to parafovea. Chromatic microperimetry demonstrated a large loss of sensitivity to red stimuli presented on a cyan adapting background at the anatomical fovea and surrounding parafovea. CONCLUSIONS: BCM rods continue to signal vision under conditions normally associated with daylight vision. Localized and retina-wide outcome measures were examined to evaluate possible improvement of L/M-cone-based vision in a clinical trial. Public Library of Science 2015-04-24 /pmc/articles/PMC4409040/ /pubmed/25909963 http://dx.doi.org/10.1371/journal.pone.0125700 Text en © 2015 Luo et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Luo, Xunda
Cideciyan, Artur V.
Iannaccone, Alessandro
Roman, Alejandro J.
Ditta, Lauren C.
Jennings, Barbara J.
Yatsenko, Svetlana A.
Sheplock, Rebecca
Sumaroka, Alexander
Swider, Malgorzata
Schwartz, Sharon B.
Wissinger, Bernd
Kohl, Susanne
Jacobson, Samuel G.
Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials
title Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials
title_full Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials
title_fullStr Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials
title_full_unstemmed Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials
title_short Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials
title_sort blue cone monochromacy: visual function and efficacy outcome measures for clinical trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409040/
https://www.ncbi.nlm.nih.gov/pubmed/25909963
http://dx.doi.org/10.1371/journal.pone.0125700
work_keys_str_mv AT luoxunda blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT cideciyanarturv blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT iannacconealessandro blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT romanalejandroj blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT dittalaurenc blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT jenningsbarbaraj blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT yatsenkosvetlanaa blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT sheplockrebecca blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT sumarokaalexander blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT swidermalgorzata blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT schwartzsharonb blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT wissingerbernd blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT kohlsusanne blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials
AT jacobsonsamuelg blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials